DDInter1763 DDInter1400
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Temsirolimus {u} (Compound) treats {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Pazopanib
Temsirolimus {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Pazopanib
Temsirolimus {u} (Compound) downregulates {v} (Gene) RCHY1
RCHY1 {u} (Gene) is upregulated by {v} (Compound) Pazopanib
Temsirolimus {u} (Compound) upregulates {v} (Gene) KIAA0355
KIAA0355 {u} (Gene) is upregulated by {v} (Compound) Pazopanib
Temsirolimus {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Protein Kinase Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Pazopanib
Temsirolimus {u} (Compound) upregulates {v} (Gene) HIST2H2BE
HIST2H2BE {u} (Gene) is downregulated by {v} (Compound) Pazopanib
Temsirolimus {u} (Compound) causes {v} (Side Effect) Aspartate aminotransferase increased
Aspartate aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Pazopanib
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Temsirolimus {u} (Compound) upregulates {v} (Gene) FGFR2
FGFR2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is downregulated by {v} (Compound) Pazopanib
Temsirolimus {u} (Compound) treats {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is associated with {v} (Gene) FLT1
FLT1 {u} (Gene) is bound by {v} (Compound) Pazopanib
Temsirolimus (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is treated by Pazopanib (Compound)
Temsirolimus (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Pazopanib (Compound)
Temsirolimus (Compound) downregulates RCHY1 (Gene) and RCHY1 (Gene) is upregulated by Pazopanib (Compound)
Temsirolimus (Compound) upregulates KIAA0355 (Gene) and KIAA0355 (Gene) is upregulated by Pazopanib (Compound)
Temsirolimus (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class) and Protein Kinase Inhibitors (Pharmacologic Class) includes Pazopanib (Compound)
Temsirolimus (Compound) upregulates HIST2H2BE (Gene) and HIST2H2BE (Gene) is downregulated by Pazopanib (Compound)
Temsirolimus (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Pazopanib (Compound)
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Temsirolimus (Compound) upregulates FGFR2 (Gene) and FGFR2 (Gene) is bound by Pazopanib (Compound) and FGFR2 (Gene) is downregulated by Pazopanib (Compound)
Temsirolimus (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is associated with FLT1 (Gene) and FLT1 (Gene) is bound by Pazopanib (Compound)